Yucel Erbilgin
Overview
Explore the profile of Yucel Erbilgin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
127
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Erbilgin Y, Firtina S, Kirat E, Khodzhaev K, Karakas Z, Unuvar A, et al.
Biochem Genet
. 2025 Jan;
PMID: 39786526
IKZF1 deletions (ΔIKZF1) are common in precursor B-cell acute lymphoblastic leukemia (B-ALL) and are assumed to have a prognostic impact. We aimed to determine the prognostic implications of ΔIKZF1 and...
2.
Erdem Y, Ozkaya E, Erbilgin Y, Saritas M, Sayitoglu M, Su Kucuk O, et al.
Dermatitis
. 2025 Jan;
PMID: 39772616
No abstract available.
3.
Khodzhaev K, Sudutan T, Erbilgin Y, Saritas M, Yegen G, Bozkurt C, et al.
Eur J Med Genet
. 2024 Sep;
72:104975.
PMID: 39322061
Hodgkin's lymphoma (HL) is the most common cancer in adolescents and young adults. A family history of HL increases the risk of developing HL in other family members. Identification of...
4.
Qipa E, Acar M, Bozkurt S, Buyukdogan M, Sonmez H, Sayitoglu M, et al.
Mediterr J Hematol Infect Dis
. 2023 Jul;
15(1):e2023036.
PMID: 37435033
Acute lymphoblastic leukemia (ALL) is a malignant disease of hematopoietic stem cells. B cell ALL (B-ALL) is characterized by highly proliferative and poorly differentiated progenitor B cells in the bone...
5.
Firtina S, Erbilgin Y, Ng O, Karaman S, Karakas Z, Celkan T, et al.
Scand J Clin Lab Invest
. 2023 Apr;
83(3):187-193.
PMID: 37029683
The () gene is one of the most studied genes in cancer. Although variants are rare events in acute leukemia, recent observations showed that relapse samples might harbor variants. Here,...
6.
Imeri J, Desterke C, Marcoux P, Telliam G, Sanekli S, Barreau S, et al.
Cells
. 2023 Feb;
12(4).
PMID: 36831265
Purpose: To model CML progression in vitro and generate a blast crisis (BC-CML) model in vitro in order to identify new targets. Methods: Three different CML-derived iPSC lines were mutagenized...
7.
Ng O, Sahin I, Erbilgin Y, Ozdemir O, Yucesan E, Erturk N, et al.
Front Public Health
. 2023 Jan;
10:1049349.
PMID: 36684907
Rare disease patients constitute a significant part of the healthcare system of all countries. However, the information on the experiences during disease processes and daily life of rare disease patients...
8.
Sudutan T, Erbilgin Y, Ng O, Karaman S, Karakas Z, Kucukcankurt F, et al.
Leuk Lymphoma
. 2022 Aug;
63(12):2931-2939.
PMID: 35921545
B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is a heterogeneous malignancy and consists of several genetic abnormalities. Some of these abnormalities are used in clinics for risk calculation and treatment decisions....
9.
Erbilgin Y, Ng O, Can I, Firtina S, Kucukcankurt F, Karaman S, et al.
Int J Lab Hematol
. 2021 Apr;
43(5):1093-1103.
PMID: 33844466
Introduction: The lymphoid enhancer factor 1 (LEF1) is a DNA-binding transcription factor that functions in the Wnt signaling pathway. Increased LEF1 activity is associated with progression of several types of...
10.
Khodzhaev K, Buyukkapu Bay S, Kebudi R, Altindirek D, Kaya A, Erbilgin Y, et al.
J Clin Immunol
. 2020 Jul;
40(6):883-892.
PMID: 32620996
Genome-wide sequencing studies in pediatric cancer cohorts indicate that about 10% of patients have germline mutations within cancer predisposition genes. Within this group, primary immune deficiencies take the priority regarding...